🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A bit more of the video Full length posted youtube.com/@EricTopolSRTI Transcript with links erictopol.substack.com/p/akiko-iwasak…

Good morning #IMMUNOLOGY2025™ attendees! It's a beautiful day for #immunology and networking!

Dr. Tyler Hulett Tyler Hulett at #CDI #puertoRico is wowing the crowd at #AAI2025 with methods to assay antibody responses in serum! They are making progress advancing the field with everything from Ab to IG isotypes to considering #DarkGenome protein arrays! #cancer #immunotherapy

Adding CDI Labs / This is the group that makes the Arrays.. CHECK IT OUT cdilabs.com/products/hupro… cdilabs.com/media/pdf/BRH-…

Today on #MelanomaMonday, we recognize the brilliant scientists and researchers around the globe working tirelessly to uncover breakthroughs and ultimately find a cure for melanoma. Their dedication to advancing our understanding of this disease and improving treatment options is

If you're attending #AAI2025 / #IMMUNOLOGY2025 in Honolulu, don’t miss the opportunity to join an engaging poster session today, Monday, May 5, at 1:15 PM HST. Tyler Hulett, PhD, CSO at CDI Labs, will be presenting his poster titled, "Massively Multiplexed Serology of

Mark your calendar! Join us next week, Tuesday, May 13, at 12 PM ET for a live webinar hosted by the Institute for Immunology and Immune Health at the University of Pennsylvania. In this thought-provoking session titled "When the Immune System Misfires: Leveraging

We are proud to share that over 275+ high-profile #publications have cited, featured, and highlighted our cutting-edge platforms and unparalleled lab services. Our unique, user-friendly Publications Portal gives you the ability to seamlessly search and explore subject matter,

Join us at #FOCIS2025 in Boston, June 24–27, at Booth 2! Discover how our cutting-edge technologies and industry-leading lab services are driving innovation and advancing breakthroughs in immune-mediated diseases. We look forward to connecting with you and exploring how we can

PUBLICATION: In their study, "The #antibody repertoire of #autoimmune sensory neuronopathies targets pathways of the innate and adaptive immune system. An autoantigenomic approach," Christian P. Moritz and colleagues conducted a retrospective cohort study using #HuProt to

Our #VirScan® PhIP-Seq viral exposure profiling enables scientists to uncover both individual and population-level histories of viral infections, providing critical insights into the dynamic spread and behavior of infectious disease. Additionally, it facilitates groundbreaking

What happens when your immune system misfires? If you missed our recent webinar, we invite you to watch as our CSO, Tyler Hulett, PhD, delves into this critical question. In this engaging session, Dr. Hulett uncovers groundbreaking insights into the complex world of autoimmunity,

What drives the pathogenic B-cell response in multiple sclerosis (MS)? A new study published in Neurology Journal sheds light on this question. Johannes Raffael Dahl and his team at Friedrich-Alexander-Universität Erlangen-Nürnberg used advanced techniques, including polyclonal

What do our #HuScan® PhIP-Seq services offer researchers? ✅ Ultimate Coverage: Detect antibodies targeting virtually any antigen using overlapping long peptides ✅ Total Proteome Profiling: Dive deep into epitope-level insights across the entire RefSeq human proteome ✅

Join us for a live webinar hosted by the Houston Omics Collaborative at the University of Houston, with Tyler Hulett, PhD. On Tuesday, June 3, at 12 PM CT / 1 PM ET, Dr. Hulett will present the second installment of "When the Immune System Misfires: Leveraging Self-Recognition

What do our #HuProt™ services offer researchers and scientists? ✅ Unmatched Content: Dive deep into human biology with access to the most extensive library of full-length human proteins available. ✅ Application Versatility: Discover new disease relevant autoantibodies,